EUVIMEDEUVIMED entdecken
Crossref

The elusive Nav1.7: From pain to cancer

Umberto Banderali, Maria Moreno, Marzia Martina

Current Topics in Membranes · 2023

DOI: 10.1016/bs.ctm.2023.09.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Topics in Membranes, 2023. Verfasst von Umberto Banderali und 2 weiteren Autor:innen. Beteiligte Einrichtung: Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal road, Ottawa, ON, Canada. Electronic address: Umberto.Bander…. Hauptthemen laut MEDLINE: Voltage-Gated Sodium Channels, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voltage-gated sodium channels (Nav) are protein complexes that play fundamental roles in the transmission of signals in the nervous system, at the neuromuscular junction and in the heart. They are mainly present in excitable cells where they are responsible for triggering action potentials. Dysfunctions in Nav ion conduction give rise to a wide range of conditions, including neurological disorders, hypertension, arrhythmia, pain and cancer. Nav family 1 is composed of nine members, named numerically from 1 to 9. A Nax family also exists and is involved in body-fluid homeostasis. Of particular interest is Nav1.7 which is highly expressed in the sensory neurons of the dorsal root ganglions, where it is involved in the propagation of pain sensation. Gain-of-function mutations in Nav1.7 cause pathologies associated with increased pain sensitivity, while loss-of-function mutations cause reduced sensitivity to pain. The last decade has seen considerable effort in developing highly specific Nav1.7 blockers as pain medications, nonetheless, sufficient efficacy has yet to be achieved. Evidence is now conclusively showing that Navs are also present in many types of cancer cells, where they are involved in cell migration and invasiveness. Nav1.7 is anomalously expressed in endometrial, ovarian and lung cancers. Nav1.7 is also involved in Chemotherapy Induced Peripheral Neuropathy (CIPN). We propose that the knowledge and tools developed to study the role of Nav1.7 in pain can be exploited to develop novel cancer therapies. In this chapter, we illustrate the various aspects of Nav1.7 function in pain, cancer and CIPN, and outline therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Voltage-Gated Sodium ChannelsNeoplasmsHumansPainGanglia, SpinalSensory Receptor CellsAction Potentials

Stichwörter der Autor:innen

Chemotherapy Induced Neuropathic Pain (CINP)Endometrial cancerGastric cancerNon-small cell lung carcinomaOvarian cancerPancreatic cancerRhabdomyosarcomaVoltage gated sodium channel (VGSC)

Substanzen

Voltage-Gated Sodium Channels

Autor:innen und Institutionen

  • Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal road, Ottawa, ON, Canada. Electronic address: Umberto.Banderali@nrc-cnrc.gc.ca.
  • Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal road, Ottawa, ON, Canada.

Zitieren

APA

Banderali, U., Moreno, M., & Martina, M. (2023). The elusive Nav1.7: From pain to cancer. Current Topics in Membranes. https://doi.org/10.1016/bs.ctm.2023.09.003

Vancouver

Banderali U, Moreno M, Martina M. The elusive Nav1.7: From pain to cancer. Current Topics in Membranes. 2023. doi:10.1016/bs.ctm.2023.09.003

BibTeX
@article{Banderali2023,
  author = {Banderali, Umberto and Moreno, Maria and Martina, Marzia},
  title = {The elusive Nav1.7: From pain to cancer},
  journal = {Current Topics in Membranes},
  year = {2023},
  doi = {10.1016/bs.ctm.2023.09.003}
}
Kostenlos starten →